Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Point of Care Testing for Infectious Disease market was valued at USD 7.55 billion in 2024. The market is projected to grow from USD 8.37 billion in 2025 to USD 15.26 billion by 2032, exhibiting a CAGR of 10.8% during the forecast period.
Point of Care Testing (POCT) for infectious diseases refers to medical diagnostic testing performed at or near the site of patient care, delivering rapid results to facilitate immediate clinical decisions. These tests are designed for simplicity and speed, utilizing technologies like lateral flow assays, molecular diagnostics, and microfluidics to detect pathogens or their biomarkers. The dominant test types include Immunological Tests, which detect antigens or antibodies, and the rapidly advancing Pathogen Nucleic Acid Tests, which offer high sensitivity by identifying genetic material.
This market's robust growth is primarily driven by the high global burden of infectious diseases and the critical need for rapid diagnostics, a need magnified by the COVID-19 pandemic. The rising prevalence of conditions like influenza, HIV, hepatitis, and sexually transmitted infections (STIs) underscores the demand for decentralized testing. Furthermore, technological advancements are making molecular POCT, or molecular diagnostics at the point of care, more accessible and affordable. The competitive landscape is dominated by key players such as Roche, Abbott, and Siemens Healthineers, who continue to innovate with compact, user-friendly platforms to capture market share in both hospital and clinic settings.
Rapid Diagnostic Needs and Pandemic Preparedness
The global emphasis on pandemic preparedness, highlighted by the COVID-19 crisis, is a primary driver for the Point of Care Testing (POCT) market for infectious diseases. The need for immediate clinical decisions in emergency departments, clinics, and community settings has accelerated adoption. Public health initiatives are increasingly funding the deployment of rapid tests to enable early detection and containment of outbreaks, reducing the strain on centralized laboratories and improving patient outcomes through timely intervention.
Technological Advancements in Assay Development
Innovations in microfluidics, biosensors, and molecular diagnostics such as isothermal amplification are making POCT devices more accurate, user-friendly, and cost-effective. The development of multiplexed tests that can detect multiple pathogens from a single sample is expanding the clinical utility of POCT. These technological improvements are increasing test sensitivity and specificity, making them reliable alternatives to traditional lab-based methods for diseases like influenza, HIV, and streptococcal infections.
➤ The global POCT market for infectious diseases is projected to experience significant growth, driven by the high demand for decentralized testing solutions that deliver results in minutes rather than hours.
Growing patient awareness and the shift towards personalized medicine are also fueling market expansion. Consumers and healthcare providers alike value the convenience and speed of point-of-care tests, which facilitate quicker treatment initiation and better management of infectious diseases in both high-income and low-resource settings.
MARKET CHALLENGES
Regulatory Hurdles and Quality Assurance
Navigating the complex regulatory landscape for medical devices remains a significant challenge. POCT tests for infectious diseases must meet stringent accuracy and reliability standards set by bodies like the FDA and EMA. Ensuring consistent quality and performance across different operators and settings, especially in decentralized environments, requires robust training and quality control protocols, which can be difficult to implement uniformly.
Other Challenges
High Development Costs and Reimbursement Issues
The initial investment for research, development, and clinical validation of new POCT devices is substantial. Furthermore, reimbursement policies for point-of-care infectious disease tests vary widely by region and payer, creating uncertainty for manufacturers and healthcare providers and potentially limiting market penetration.
Limited Test Menu and Connectivity
While advancements are being made, the menu of available tests for infectious diseases at the point of care is still limited compared to central laboratories. Integrating POCT devices with electronic health records (EHRs) for seamless data management also presents technical and interoperability challenges that can hinder widespread adoption.
Accuracy and Reliability Concerns
Despite improvements, some POCT devices for infectious diseases may have lower sensitivity or specificity compared to laboratory-based gold standard methods. This can lead to concerns about false negatives or positives, particularly for diseases requiring high diagnostic precision. Such limitations can restrain adoption in settings where diagnostic certainty is critical, potentially slowing market growth in certain segments.
Economic and Infrastructure Limitations
The cost of POCT devices and consumables can be a barrier to adoption, especially in low- and middle-income countries where healthcare budgets are constrained. Additionally, a lack of stable infrastructure, such as reliable electricity or cold chain storage for reagents, can limit the deployment and effectiveness of these tests in resource-poor settings, restraining market expansion in these regions.
Expansion into Decentralized Healthcare Settings
There is a significant opportunity to expand the use of POCT for infectious diseases beyond traditional hospitals into pharmacies, workplaces, schools, and home care settings. The growing trend of telehealth and remote patient monitoring creates a synergistic demand for rapid diagnostic tools that can be used by patients or non-specialist healthcare workers, opening new revenue streams for market players.
Emerging Markets and Untapped Pathogens
Emerging economies with large populations and growing healthcare expenditures represent a major growth opportunity. Furthermore, the development of POCT for neglected tropical diseases or emerging pathogens, such as new variants of concern for respiratory viruses, presents a fertile ground for innovation and market differentiation. Partnerships with global health organizations can facilitate entry into these new markets and disease areas.
Integration of Artificial Intelligence and Data Analytics
The incorporation of AI algorithms into POCT devices can enhance diagnostic accuracy by interpreting complex results and identifying patterns. This integration also enables real-time data collection for public health surveillance, offering opportunities for manufacturers to develop value-added, connected diagnostic solutions that appeal to public health agencies and larger healthcare systems.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Immunological Test is the most established segment, valued for its rapid turnaround time, cost-effectiveness, and proven utility in detecting antigens and antibodies for a wide range of infectious diseases like influenza, HIV, and streptococcus. Its simplicity and suitability for decentralized testing environments have driven widespread adoption. The Pathogen Nucleic Acid Test segment is experiencing dynamic growth, propelled by its superior sensitivity and specificity, which are critical for accurate diagnosis of pathogens with low viral loads or for differentiating between similar infections, making it indispensable in complex clinical scenarios. |
| By Application |
|
Hospitals represent the dominant application segment due to their high patient volume, need for urgent diagnostics in emergency departments and intensive care units, and the requirement for comprehensive infectious disease management protocols. The ability to obtain results within minutes directly influences critical treatment decisions, patient isolation needs, and antibiotic stewardship. Clinics and other decentralized settings, including pharmacies and workplace screening programs, are rapidly expanding their adoption, driven by the demand for greater patient accessibility, convenience, and the shift towards community-based healthcare models for managing both chronic and acute infectious conditions. |
| By End User |
|
Diagnostic Laboratories are the leading end users, leveraging POCT to enhance workflow efficiency by offloading routine and urgent tests from central labs, thereby reducing turnaround times for clinicians and patients. The Home Care Settings segment is an area of significant growth and innovation, empowered by user-friendly testing kits that enable individuals to monitor chronic infections or screen for common illnesses, fostering proactive health management. Research Institutes utilize these tests for epidemiological studies, clinical trials, and validating new diagnostic markers, contributing to the continuous evolution of testing technologies. |
| By Technology Platform |
|
Lateral Flow Assays are the cornerstone of the POCT market, prized for their simplicity, low cost, and robust performance in detecting a vast array of infectious agents, making them ideal for mass screening and resource-limited settings. The Molecular Diagnostics platform is the most rapidly advancing segment, offering gold-standard accuracy through technologies like PCR and isothermal amplification, which are increasingly being miniaturized for near-patient use to provide definitive results for complex diseases. Microfluidics-based platforms are emerging as a key enabler for sophisticated multi-parameter testing on a single, compact cartridge, driving the trend towards lab-quality results in a truly portable format. |
| By Pathogen Type |
|
Respiratory Infections constitute the largest pathogen segment, driven by the high global burden of diseases like influenza, COVID-19, and RSV, where rapid diagnosis is critical for infection control and appropriate antiviral therapy. Testing for Sexually Transmitted Infections is a high-growth area, as POCT enables discreet, immediate testing and counseling, which is vital for public health initiatives aimed at reducing transmission and improving treatment outcomes. The segment for Healthcare-Associated Infections is increasingly important, with POCT used for rapid screening of patients for pathogens like MRSA and C. difficile upon admission to prevent outbreaks within healthcare facilities. |
Market Dominated by Established Global Diagnostics Giants and Innovative Niche Players
The global Point of Care Testing (POCT) for Infectious Disease market features a consolidated competitive landscape where the top five players collectively hold a significant revenue share. This dominance is anchored by multinational diagnostics corporations such as Roche and Abbott, which leverage their extensive R&D capabilities, robust global distribution networks, and diversified portfolios of immunoassay and molecular diagnostic platforms. These industry leaders are continuously innovating, focusing on developing rapid, high-sensitivity tests for a broad range of infectious diseases, including respiratory infections, sexually transmitted diseases (STDs), and healthcare-associated infections (HAIs). Their strategic focus includes expanding into emerging markets and integrating connectivity features for seamless data management within healthcare systems.
Beyond the major players, the market includes several other significant companies that compete through specialization and regional strength. Siemens Healthineers and Danaher (through its subsidiary Cepheid) are key competitors with strong offerings in automated POCT systems and molecular diagnostics. Companies like BioMerieux and QuidelOrtho excel in specific test segments, such as influenza and streptococcal testing. The landscape is further enriched by prominent regional players, particularly in Asia, such as Wondfo and Sinocare from China, which offer cost-effective solutions and have gained substantial market share in their domestic and neighboring markets. These companies often compete on price and agility, addressing the needs of decentralized testing settings like clinics and pharmacies.
List of Key Point of Care Testing for Infectious Disease Companies ProfiledRoche
LifeScan
Danaher
Ascensia
ARKRAY
Sinocare
Wondfo
Yuwell
Runbio
KHB
BD (Becton, Dickinson and Company)
The global Point of Care Testing for Infectious Disease market is undergoing a period of robust growth, projected to expand from a value of $7554 million in 2024 to $15260 million by 2032, achieving a compound annual growth rate (CAGR) of 10.8%. This significant growth is primarily driven by the critical need for rapid diagnostic results to facilitate immediate clinical decisions, particularly during outbreaks and in resource-limited settings. The demand for quick, accurate testing has cemented POCT's role as an indispensable tool in modern healthcare, moving diagnostics closer to the patient. North America, particularly the United States, continues to be a major market, while China is expected to exhibit substantial growth, reflecting increasing healthcare investments and infrastructure development.
Other TrendsSegmentation by Test Type: Immunological and Molecular Diagnostics
The market is segmented by test type, with Immunological Tests constituting a significant portion of the revenue. This segment is poised for continued growth due to its speed, ease of use, and broad applicability for detecting various infectious agents. Concurrently, the Pathogen Nucleic Acid Test segment is emerging as a high-growth area, driven by its superior sensitivity and specificity. The adoption of molecular POCT platforms, which deliver laboratory-quality results in minutes, is accelerating, especially for complex pathogens like HIV, hepatitis, and sexually transmitted infections, revolutionizing disease management.
Competitive Landscape and Strategic DevelopmentsThe competitive environment features a concentration of key global players, including Roche, Abbott, Siemens Healthineers, Danaher, and BioMerieux, which collectively held a significant share of the market revenue in 2024. The competitive intensity is fostering continuous innovation, with companies actively engaged in developing more portable, user-friendly, and interconnected devices. Strategic activities such as mergers, acquisitions, and partnerships are common as companies seek to expand their product portfolios and geographic reach. The market is also seeing increased participation from regional players like Wondfo and Sinocare, intensifying competition and driving technological accessibility.
Regional Analysis: Point of Care Testing for Infectious Disease MarketEurope
Europe represents a highly significant and mature market for POCT in infectious diseases, characterized by robust healthcare systems and concerted efforts toward standardizing care pathways. The region benefits from strong government support for public health initiatives and a growing emphasis on cost-effective healthcare delivery. There is increasing adoption of POCT to reduce hospital admissions and streamline patient flow in clinics. Countries like Germany, the UK, and France are at the forefront, driven by advanced laboratory infrastructure and high awareness among medical professionals. The European market is also shaped by stringent regulatory standards set by institutions, ensuring high-quality and reliable diagnostic tools. A key trend is the integration of POCT into antimicrobial stewardship programs to combat resistance, alongside a rising focus on tests for tropical and travel-related diseases due to high mobility within and outside the region.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for infectious disease POCT, propelled by its large population, rising healthcare expenditure, and increasing focus on improving healthcare accessibility in rural and remote areas. Countries such as China, India, and Japan are major contributors, with governments actively promoting point-of-care solutions to manage infectious disease burdens like tuberculosis, dengue, and hepatitis. The market growth is fueled by the need for rapid diagnostics in primary care settings to bridge urban-rural health disparities. While infrastructure development varies widely, there is a strong trend towards adopting affordable and portable testing devices. Local manufacturing capabilities are expanding, making tests more accessible. However, market dynamics are also influenced by diverse regulatory landscapes and reimbursement policies across different countries within the region.
South America
South America's market for infectious disease POCT is evolving, driven by the need to combat endemic diseases and improve public health responses. Nations like Brazil and Argentina are key markets, where POCT is increasingly used for managing outbreaks of diseases such as Zika, dengue, and chikungunya. The region faces challenges related to economic volatility and disparities in healthcare access, but there is growing governmental and international support for strengthening diagnostic capabilities. POCT is seen as a crucial tool for screening in hard-to-reach communities and for surveillance programs. The market is characterized by a focus on affordability and simplicity of use. Partnerships between public health agencies and diagnostic companies are instrumental in driving adoption, although infrastructure limitations in some areas can hinder widespread implementation.
Middle East & Africa
The Middle East and Africa region presents a diverse and opportunistic landscape for POCT in infectious diseases, marked by significant variations in economic development and healthcare infrastructure. The Gulf Cooperation Council (GCC) countries exhibit advanced healthcare systems with high adoption rates of modern POCT technologies for hospital infection control and travel medicine. In contrast, many parts of Africa utilize POCT as a cornerstone for managing high-burden infectious diseases like HIV/AIDS, malaria, and tuberculosis, often supported by international aid organizations. The key market dynamic is the critical role of POCT in resource-limited settings, where it enables diagnosis without sophisticated laboratory support. Challenges include supply chain issues and ensuring quality assurance, but the focus on strengthening primary healthcare and outbreak response is creating gradual market growth across the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Healthcare providers and hospitals
Diagnostic equipment manufacturers
Biotech and pharmaceutical companies
Research institutions and laboratories
Investors, consultants, and policymakers
-> Global Point of Care Testing for Infectious Disease market was valued at USD 7.55 billion in 2024 and is expected to reach USD 15.26 billion by 2032.
-> Key players include Roche, Abbott, LifeScan, Siemens Healthineers, and Danaher, among others.
-> The market is projected to grow at a CAGR of 10.8% during 2025-2032.
-> Immunological Tests and Pathogen Nucleic Acid Tests dominate the market.
-> Major applications include hospitals, clinics, and other healthcare settings.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates